Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. To evaluate the efficacy and safety of nirsevimab through a sys...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatrics and neonatology
Main Authors:	Lien, Hsin-Chweng, Lien, Chi-Hone, Liu, Tzu-Yu, Weng, Shun-Long, Tai, Yu-Lin, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, Yeung, Chun-Yan, Lin, Chien-Yu
Format:	Journal Article
Language:	English
Published:	Singapore Elsevier B.V 13.11.2025
Subjects:	Beyfortus Internal Medicine Monoclonal antibody Nirsevimab Passive immunity Pediatrics Respiratory syncytial virus RSV Seasonality Traveller Beyfortus Respiratory syncytial virus RSV Seasonality Passive immunity Monoclonal antibody Traveller Nirsevimab passive immunity monoclonal antibody respiratory syncytial virus traveller seasonality nirsevimab
ISSN:	1875-9572, 2212-1692, 2212-1692
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!